Lataa...
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release
[Image: see text] Histone deacetylase inhibitors (HDACi) target abnormal epigenetic states associated with a variety of pathologies, including cancer. Here, the development of a prodrug of the canonical broad-spectrum HDACi suberoylanilide hydroxamic acid (SAHA) is described. Although hydroxamic aci...
Tallennettuna:
| Julkaisussa: | J Med Chem |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Chemical
Society
2015
|
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4467547/ https://ncbi.nlm.nih.gov/pubmed/25974739 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.5b00539 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|